Nov 15 |
Aura Biosciences: Mid-2024 Data Could Bring Expansion Opportunity
|
Nov 12 |
David Johnson Bought 232% More Shares In Aura Biosciences
|
Nov 10 |
Aura Biosciences director David Johnson buys common shares worth ~$1.44M
|
Nov 10 |
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying
|
Nov 10 |
Aura Biosciences GAAP EPS of -$0.48
|
Nov 7 |
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
|
Nov 7 |
Aura Biosciences Announces Pricing of Public Offering of Common Stock
|
Nov 6 |
Aura Biosciences announces proposed public offering of common stock
|
Nov 6 |
Aura Biosciences Announces Proposed Public Offering of Common Stock
|
Nov 6 |
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
|